Nonalcoholic fatty liver disease (NAFLD) is increasingly prevalent and represents a growing
challenge in terms of prevention and treatment. Despite its high prevalence, only a small …

Non-alcoholic fatty liver disease (NAFLD) and metabolic syndrome (MS) are two different
entities sharing common clinical and physio-pathological features, with insulin resistance …

Based on the assumption that characterizing the history of a disease will help in improving
practice while offering a clue to research, this article aims at reviewing the history of …

Alterations of hepatic metabolism are critical to the development of liver disease. The
peroxisome proliferator-activated receptor-γ coactivators (PGC1s) are able to orchestrate, on …

Metabolic reprogramming is critically involved in the development and progression of
cancer. In particular, lipid metabolism has been investigated as a source of energy, micro …

Introduction: Triglyceride accumulation in the liver is an early feature in the development of
nonalcoholic fatty liver disease (NAFLD) associated with human obesity, which is a …

The farnesoid X receptor (FXR) is a bile acid activated nuclear receptor. Zucker (fa/fa) rats,
harboring a loss of function mutation of the leptin receptor, develop diabetes, insulin …

Steatosis of the liver may arise from a variety of conditions, but the molecular basis for lipid
droplet formation is poorly understood. Although a certain amount of lipid storage may even …

Fatty liver disease comprises a spectrum ranging from simple steatosis to steatohepatitis
which can progress to liver cirrhosis and hepatocellular cancer. Hepatic lipotoxicity may …

Non-Alcoholic Fatty Liver Disease (NAFLD) is caused by the accumulation of fat in over 5%
of hepatocytes in the absence of alcohol consumption. NAFLD is considered the hepatic …